Phase I Study Evaluating Dose De-escalation of Sorafenib with Metformin and Atorvastatin in Hepatocellular Carcinoma (SMASH)

BACKGROUND: This phase I dose de-escalation study aimed to assess the tolerability, safety, pharmacokinetics (PK), and efficacy of sequentially decreasing doses of sorafenib in combination (SAM) with atorvastatin (A, 10 mg) and metformin (M, 500 mg BD) in patients with advanced hepatocellular carcin...

Descripción completa

Detalles Bibliográficos
Autores principales: Ostwal, Vikas, Ramaswamy, Anant, Gota, Vikram, Bhargava, Prabhat G, Srinivas, Sujay, Shriyan, Bharati, Jadhav, Shraddha, Goel, Mahesh, Patkar, Shraddha, Mandavkar, Sarika, Naughane, Deepali, Daddi, Anuprita, Nashikkar, Chaitali, Shetty, Nitin, Ankathi, Suman Kumar, Banavali, Shripad D
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Clinical Trial Results
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8914502/
https://www.ncbi.nlm.nih.gov/pubmed/35274724
http://dx.doi.org/10.1093/oncolo/oyab008

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8914502/
https://www.ncbi.nlm.nih.gov/pubmed/35274724
http://dx.doi.org/10.1093/oncolo/oyab008

Ejemplares similares